Efgartigimod (VYVGART)
Generalized Myasthenia Gravis (gMG)
ApprovedCommercial
Key Facts
About Argenx
Argenx is a mission-driven immunology company dedicated to improving the lives of patients with severe autoimmune diseases through innovative antibody therapies. Its core achievement is the successful global commercialization of efgartigimod (VYVGART®), a first-in-class FcRn blocker, establishing a commercial foundation and validating its platform. The company's strategy centers on expanding efgartigimod's label into multiple autoimmune indications while advancing a broad, deep pipeline of novel candidates from its proprietary SIMPLE Antibody™ platform, aiming to build a leading, fully integrated immunology franchise.
View full company profileTherapeutic Areas
Other Generalized Myasthenia Gravis (gMG) Drugs
| Drug | Company | Phase |
|---|---|---|
| ignaseclant (NMD670) | NMD Pharma | Phase 2 |
| Anitocabtagene Autoleucel (anito-cel) | Arcellx | Phase 1 |
| DNTH103 | Dianthus Therapeutics | Phase 1b |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |
| Descartes-08 | Cartesian Therapeutics | Phase 2b |